Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLESTIPOL HYDROCHLORIDE vs COLESTID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Primary hypercholesterolemia (FDA-approved adjunct to diet),Pruritus associated with partial biliary obstruction,Pseudomembranous enterocolitis (off-label, as colestipol binds Clostridium difficile toxins),Digitoxin toxicity (off-label, to interrupt enterohepatic circulation),Bile acid malabsorption (off-label)
Adjunctive therapy to diet for reduction of elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia (type IIa) who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Digoxin toxicity (off-label),Hyperthyroidism (off-label),Pseudomembranous colitis (off-label)
Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.
5-10 g orally once or twice daily, maximum 30 g/day.
Not applicable as colestipol is not absorbed; it acts locally in the gastrointestinal tract and has no systemic half-life.
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Not metabolized; not absorbed systemically.
Not absorbed systemically; not metabolized; excreted unchanged in feces.
Colestipol hydrochloride is not absorbed systemically; it is excreted entirely in the feces as the intact polymer, without undergoing metabolism. No renal or biliary elimination occurs.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Not applicable; the drug is not absorbed and does not bind to plasma proteins.
Not significantly absorbed; binding not applicable
Not applicable; colestipol is not absorbed and remains within the gastrointestinal lumen.
Not applicable (non-absorbed; confined to gastrointestinal lumen)
0% for systemic absorption; it is non-absorbable and acts locally in the intestine.
Oral: <0.05% (negligible systemic absorption)
No specific dose adjustment recommended; use with caution in severe renal impairment due to potential for hyperchloremic metabolic acidosis.
No specific dosage adjustment required for renal impairment; use with caution in patients with renal dysfunction due to potential for hyperchloremic metabolic acidosis.
No specific dose adjustment recommended; caution in severe hepatic impairment due to possible decreased cholesterol synthesis.
No specific dosage adjustment required for hepatic impairment; use with caution in patients with pre-existing gastrointestinal disorders.
Not established for children <10 years; for ≥10 years, initial: 5 g orally once daily; increase gradually to 5-20 g/day divided once or twice daily.
Safety and efficacy not established; limited data suggest 5-10 g daily in divided doses for children aged 12-18 years.
No specific dose adjustment; monitor for gastrointestinal adverse effects and potential interactions with other medications due to altered GI motility and polypharmacy.
No specific dosage adjustment; monitor for constipation and gastrointestinal adverse effects; initiate at low end of dosing range.
No FDA black box warning.
No FDA black box warning.
May cause hypertriglyceridemia,Risk of vitamin K deficiency and bleeding (due to bile acid binding),May impair absorption of fat-soluble vitamins (A, D, E, K),May cause constipation or fecal impaction (especially in elderly),May interfere with absorption of other drugs (e.g., warfarin, thyroid hormones, digoxin); separate administration by at least 1 hour or as specified
May cause fecal impaction, especially in patients with hemorrhoids or constipation.,May interfere with absorption of fat-soluble vitamins (A, D, E, K).,May reduce absorption of other drugs; take other medications at least 1 hour before or 4-6 hours after colestipol.,Use with caution in patients with bleeding tendencies or with impaired hepatic function.,Hypertriglyceridemia may occur.
Hypersensitivity to colestipol hydrochloride or any component,Complete biliary obstruction,Phenylketonuria (if formulation contains aspartame)
Complete biliary obstruction,Hypersensitivity to colestipol or any component of the formulation
Colestipol can bind to dietary fats and fat-soluble vitamins (A, D, E, K). Take supplements at least 1 hour before or 4-6 hours after colestipol. High-fiber foods may reduce binding but are generally encouraged to prevent constipation. Avoid grapefruit juice? No significant interaction.
Colestipol may bind to fat-soluble vitamins (A, D, E, K) and decrease their absorption. Take vitamin supplements at least 1 hour before or 4 hours after colestipol. High-fat meals may reduce binding efficacy; take with meals containing moderate fat.
Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known adverse fetal effects.
FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefore, fetal risk is considered minimal. Trimester-specific risks: First trimester: No known risk due to lack of absorption. Second and third trimesters: Potential for decreased absorption of fat-soluble vitamins and folate, which may affect fetal development. Vitamin K deficiency may increase neonatal bleeding risk.
Colestipol is not absorbed systemically and not excreted into breast milk. Compatible with breastfeeding. M/P ratio not applicable.
Colestipol is not absorbed systemically, thus is not expected to be excreted into breast milk. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for potential gastrointestinal effects secondary to maternal use.
No dose adjustment required due to lack of systemic absorption. Monitor for potential fat-soluble vitamin deficiency and supplement if needed.
No dose adjustment required due to lack of systemic absorption. However, ensure adequate nutritional status: monitor fat-soluble vitamin supplementation (A, D, E, K) and folate; increase interval between colestipol and prenatal vitamins/food to 1 hour before or 4 hours after.
Colestipol hydrochloride is a bile acid sequestrant used as adjunctive therapy for primary hyperlipidemia. It may increase triglyceride levels; monitor triglycerides before initiation. Administer other medications 1 hour before or 4-6 hours after colestipol to reduce absorption interference. Use with caution in constipation-prone patients; encourage high-fiber diet and adequate fluid intake. Can bind thyroxine, warfarin, digoxin, and fat-soluble vitamins.
Colestipol is a bile acid sequestrant; administer with meals to bind bile acids. Monitor for constipation and increase fluid/fiber intake. Reduce doses of other medications by at least 1 hour before or 4 hours after colestipol. May increase triglyceride levels; monitor lipids. Use with caution in patients with renal impairment.
Take colestipol with meals and plenty of water (at least 8 oz).,Do not take other medications within 1 hour before or 4-6 hours after colestipol.,May cause constipation; increase dietary fiber and fluid intake.,Report severe constipation, abdominal pain, or unusual bleeding.,Continue prescribed diet and exercise regimen.,Store at room temperature; do not freeze.
Take exactly as prescribed, usually once or twice daily with food and a full glass of water.,Do not take other medications within 1 hour before or 4 hours after colestipol.,Drink plenty of fluids and eat high-fiber foods to prevent constipation.,Inform your doctor if you have a history of hemorrhoids or digestive problems.,Keep out of reach of children; store at room temperature.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLESTIPOL HYDROCHLORIDE vs COLESTID, answered by our medical review team.
COLESTIPOL HYDROCHLORIDE is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.. COLESTID is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLESTIPOL HYDROCHLORIDE and COLESTID depend on the specific clinical indication. These are both Bile Acid Sequestrant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLESTIPOL HYDROCHLORIDE is: Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.. The standard adult dose of COLESTID is: 5-10 g orally once or twice daily, maximum 30 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLESTIPOL HYDROCHLORIDE and COLESTID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLESTIPOL HYDROCHLORIDE is classified as Category C. Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known . COLESTID is classified as Category C. FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefor. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.